ASCO defines meaningful

Share this article:

The American Society for Clinical Oncology is putting a definition to the FDA's term “clinically meaningful outcome.” BioCentury reports that the professional organization published its recommendations in the Journal of Clinical Oncology and developed guidelines for what constitutes "meaningful" in trials for pancreatic, breast, lung and colon cancers.

The group used overall survival as the primary endpoint and recommended a benchmark, such as establishing a period of 4 to 6 months, as the minimum median OS improvement for untreated, metastatic, triple-negative breast cancer.

The group also said the experimental treatments should not include a higher toxicity than current treatments.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.